When it comes to repurposed drugs, ivermectin is a wild card that’s gone from Nobel-winning antiparasitic to COVID-19 controversy, and now, a potential cancer therapy. So what’s hype, what’s hope, and what’s actually happening under the microscope?
The Science: What Ivermectin Does to Cancer Cells
1. Multiple Mechanisms of Action
Ivermectin’s anticancer activity is surprisingly broad. Studies have shown it can inhibit the proliferation (growth), metastasis (spread), and angiogenesis (blood vessel formation) of various cancer cells, while often sparing normal cells. Here’s where it gets interesting: ivermectin doesn’t just kill cancer cells through one trick, but acts on several pathways at once.
Blocks Cellular Signaling: Ivermectin interferes with pathways that cancer cells use to grow and survive—mainly the WNT/β-catenin, Hedgehog, and PAK1 signaling cascades. These pathways are commonly hijacked by tumors to fuel uncontrolled cell division and resist therapy. By disrupting them, ivermectin essentially throws a wrench into the cancer cell’s internal wiring (Taylor & Francis, PMC).
Induces Programmed Cell Death: Ivermectin pushes cancer cells toward apoptosis (programmed cell death), a process that’s often defective in tumors. It can trigger mitochondrial dysfunction—basically, it sabotages the cell’s energy factory—leading to cell death (OncoDaily).
Overcomes Drug Resistance: One of cancer’s nastiest tricks is developing resistance to chemotherapy. Ivermectin is known to reverse multidrug resistance by inhibiting P-glycoprotein and other drug-efflux pumps, making cancer cells more sensitive to conventional treatments (Ovid).
Targets Cancer Stem Cells: Early research suggests ivermectin can attack cancer stem-like cells, which are believed to drive recurrence and resistance in many tumors (Taylor & Francis).
Immune Modulation: There’s evidence ivermectin can modulate the tumor microenvironment and may boost the immune system’s ability to recognize and attack cancer cells, especially when combined with immunotherapies (NIH).
2. What Cancers Are Affected?
Lab and animal studies have shown promising results in a wide range of cancers, including breast, prostate, colon, brain, leukemia, and melanoma. Some of the most robust data comes from breast and colon cancer models, as well as drug-resistant cancers (PMC, Frontiers in Pharmacology).
The Clinical Reality: Where Are We Now?
Despite the compelling lab data, there is no robust clinical evidence or FDA approval for ivermectin as a cancer treatment in humans. Most research remains in the preclinical stage—petri dishes and animal models. A few early-phase clinical trials are underway, such as a study investigating ivermectin combined with immunotherapy for triple-negative breast cancer (ClinicalTrials.gov), but results are still pending.
The National Cancer Institute and other groups are studying ivermectin’s “ability to kill cancer cells,” but no one in mainstream oncology is recommending it outside clinical trials (KFF Health News, Cancer Therapy Advisor).
Safety and Cautions
While ivermectin is generally safe at antiparasitic doses, the doses required for anticancer effects in animal studies are often much higher, and side effects can become a concern. Self-medicating or using “veterinary” ivermectin is dangerous and not supported by evidence (Drugs.com). I don't know about you but I have to ask why? WHY is it dangerous? No answer.
Where the Research Is Headed
- Combination Therapy: Researchers are particularly interested in using ivermectin alongside chemotherapy, immunotherapy, or targeted drugs, to see if it can enhance the effectiveness or overcome resistance.
- Targeting Specific Cancers: Trials are focusing on aggressive and drug-resistant cancers, where new options are desperately needed.
- Precision Dosing: Figuring out how to deliver ivermectin safely at effective concentrations for cancer remains a major challenge.
The Bottom Line
Ivermectin is not a miracle cure, but its ability to hit multiple cancer pathways at once makes it a fascinating research candidate. The excitement is real in the lab, but for patients, it’s still an experimental story—one that needs much more clinical evidence before it becomes part of routine cancer care.
Credits:
- Progress in understanding the molecular mechanisms underlying the antitumour effects of ivermectin – Taylor & Francis
- The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug – PMC
- Antiparasitic Drug Ivermectin and Immunotherapy for Cancer – OncoDaily
- Ivermectin, a potential anticancer drug derived from an antiparasitic agent – Ovid
- US Cancer Institute Studying Ivermectin’s ‘Ability To Kill Cancer Cells’ – KFF Health News
- Giving ivermectin with pembrolizumab may increase the effect of pembrolizumab – ClinicalTrials.gov
- Official stance on ivermectin as cancer treatment – Drugs.com
